马年启幕，科技成长主线仍然如火如荼前进。2025年以来，围绕公募基金高质量发展主线与市场机遇， 大成基金持续推出"科技远光灯"系列优质投资者教育活动。1月29日，大成基金"科技远光灯"投教同行 会上海专场成功举办。 活动期间，指数与期货投资部执行总监孙雨、股票投资部基金经理郭玮羚分别进行深度分享。其中，孙 雨以"乘势而上.行稳致远"为题，对2026年度市场特征以及指数布局策略进行解读。郭玮羚则紧密贴合 市场热点，对其擅长的科技成长风格投资进行分享，解析2026年度科技板块产业投资机会，对产业链关 键环节及其投资逻辑进行专业分析。 孙雨指出，2026年开年，市场行情呈现典型的资金驱动特征，存在一定"春季躁动"特点。在无风险利率 持续下行的背景下，银行理财收益率走低，权益资产成为多元配置中的优选。政策层面持续引导中长期 资金入市，险资、理财等机构资金稳步增配，为市场构筑了坚实的基础。 孙雨强调，当前行情本质是"强预期弱现实"，情绪与资金主导短期波动。在科技成长主线持续活跃的背 景下，也需警惕部分赛道交易拥挤与估值偏高带来的回调风险。投资者应树立"慢牛长牛"思维，在拥抱 趋势的同时保持理性，方能行稳致远。 在"金字 ...

Group 1 - The major indices collectively rose on February 3, with the National Bio-Medical Index (399441) increasing by 1.15%. Notable stocks included Zhaoyan New Drug and Aimeike, both rising over 4%, while Tigermed and Huaxi Biological increased by over 3%, and Kailaiying rose nearly 3% [1] - The Bio-Medical ETF (159859) had a trading volume exceeding 65 million yuan, ranking first among its peers. The net inflow for this ETF on the previous trading day (February 2) was 67.29 million yuan, and it has seen continuous net inflows over the past 10 days, accumulating over 440 million yuan [1] - The latest circulating share of the Bio-Medical ETF is 9.569 billion shares, with a total market size of 3.674 billion yuan, making it the largest in its category [1] Group 2 - The Shanghai Municipal Government's work report emphasized the need to deepen the construction of an international economic center, focusing on modern industrial systems and supporting sectors such as bio-medicine, integrated circuits, and artificial intelligence [2] - According to Zhongtai Securities, the pharmaceutical market opportunities are expected to revolve around thematic opportunities, with potential performances in brain-computer interfaces, AI healthcare, and small nucleic acids. There is also a strategic emphasis on the raw material drug sector, which is at a bottom range and may see a mid-term positive cycle due to rising chemical prices and new business additions [2]

Core Insights - The healthcare sector in Hong Kong is experiencing significant growth opportunities driven by advancements in brain-computer interfaces, AI healthcare, and CXO services [2][18]. Group 1: Brain-Computer Interfaces - Neuralink, a company owned by Elon Musk, has commenced mass production, indicating a strong push in brain technology [2][18]. - Strong Brain Technology has completed a financing round of 2 billion yuan and is preparing for an IPO [2][18]. Group 2: AI Healthcare - Major AI companies are entering the healthcare space, with Alibaba launching "Ant Aifu" and OpenAI introducing ChatGPT Health [3][18]. Group 3: CXO Services - Companies such as WuXi AppTec, Tigermed, and Zhaoyan New Drug are forecasting net profits exceeding 100% for 2025, indicating positive performance expectations in the CXO sector [4][18]. Group 4: Market Performance - The healthcare index has shown high elasticity and volatility, with a maximum increase of 148.52% during the last pharmaceutical bull market, significantly outperforming comparable indices [8][22]. - The maximum decline since 2021 for the healthcare index was -80.73%, while the cumulative return since inception is -0.93% [10][24]. Group 5: Investment Opportunities - The Hong Kong Stock Connect Medical ETF provides a streamlined way to invest in leading healthcare companies in Hong Kong [20]. - The healthcare sector is characterized by high volatility, making it an attractive option for investors looking for significant returns [8][22].

Group 1 - The core viewpoint of the article highlights ongoing investment opportunities in the pharmaceutical sector, particularly in thematic areas such as brain-computer interfaces, AI healthcare, and small nucleic acids, with a strategic focus on the raw materials pharmaceutical sector [1] - The biopharmaceutical ETF (512290) has seen a continuous net inflow of over 460 million yuan for 10 consecutive days, indicating strong market interest [1] - The raw materials pharmaceutical sector is currently at a price bottom, with expectations of recovery driven by rising chemical prices and the introduction of new business lines such as small nucleic acids and peptides, which may lead to a mid-term positive cycle [1] Group 2 - The CS Biomedicine Index (930726), which the biopharmaceutical ETF tracks, selects listed companies involved in biotechnology, pharmaceuticals, and related life sciences from the Shanghai and Shenzhen markets to reflect the overall performance of the biopharmaceutical sector [1] - The rising prices of chemical products are expected to create cost pressures that will benefit integrated leading companies with cost advantages along the industry chain [1] - Innovative therapies such as GLP-1, small nucleic acid chronic disease drugs, and ADCs are generating significant global demand for APIs and intermediates, providing a second growth curve for raw material pharmaceutical companies [1]

Core Viewpoint - The Shanghai government aims for a GDP growth of around 5% for the year, with a focus on developing future industries and enhancing the modern industrial system [1][2][3] Economic Goals - The expected GDP growth for Shanghai in 2026 is also around 5%, with a target GDP of 5.67 trillion yuan by 2025, reflecting a growth of 5.4% [2] - Local general public budget revenue is projected to reach 850 billion yuan, with a growth of 1.5% [2] - The report sets a goal for R&D expenditure to be approximately 4.6% of the city's GDP, with an urban unemployment rate targeted to remain within 5% [2] Industry Development - The report emphasizes the cultivation of future industries such as brain-computer interfaces and fourth-generation semiconductors [3] - Implementation of the "Artificial Intelligence +" initiative is highlighted, focusing on enhancing computing power infrastructure and promoting the use of new intelligent terminals and models [3] - The construction of high-level innovation communities and the development of specialized industrial parks are prioritized [3] Investment and Infrastructure - A total of 255 billion yuan is planned for major engineering investments this year, including the construction of various metro lines and significant infrastructure projects [4] - The report outlines the initiation of several key transportation projects, including the extension of existing metro lines and the construction of new railways [4] Financial Reforms - The report calls for deepening financial system reforms and enhancing the construction of the Sci-Tech Innovation Board [5] - It aims to improve the connectivity of bond markets and explore the establishment of an offshore financial system [5] - There is a focus on fostering long-term and patient capital, enhancing the integration of finance and industry, and supporting sectors such as technology innovation and green development [5] Social Services - The report includes plans to reform elderly care services, with the addition of 2,000 cognitive care beds and 200 community-based elderly service stations [5] - It emphasizes the need for diverse services in community elderly care, including meal assistance and medical support [5]

Economic Growth and Development - Shanghai's GDP is projected to reach 5.67 trillion yuan with a growth rate of 5.4% by 2025 [2] - The total import and export volume is expected to reach 4.51 trillion yuan, with exports growing by 10.8% [6] Financial and Technological Reforms - The government aims to enhance the construction of the Sci-Tech Innovation Board and promote financial system reforms [2] - A focus on developing offshore financial systems and improving cross-border financial services is highlighted [2] Industry and Innovation - R&D expenditure is expected to account for approximately 4.5% of Shanghai's GDP by 2025 [4] - The output of strategic emerging industries is projected to grow by 6.5%, with integrated circuits, biomedicine, and artificial intelligence expected to exceed 2 trillion yuan [4] Foreign Investment and Projects - Actual foreign investment is anticipated to reach 16.06 billion USD (approximately 114.8 billion yuan) [6] - The government plans to attract foreign investment in advanced manufacturing, modern services, and high-tech industries [6] Consumer Market and Tourism - The government aims to boost consumption and develop Shanghai into an international consumption center [8] - Plans include enhancing service consumption and promoting various tourism initiatives [8] Cultural and Creative Industries - The report emphasizes the importance of cultural industry projects and the development of new cultural formats [9] - The government aims to improve the capabilities of the cultural industry, including film production and creative design [9]

Core Viewpoint - The healthcare sector in A-shares is experiencing a significant rally, driven by AI healthcare and CXO concepts, with notable inflows into medical ETFs [1][8]. Group 1: ETF Performance - The largest medical ETF in A-shares (512170) saw an intraday increase of over 1%, recovering its annual line, with a net subscription of 2.633 billion yuan over the past 10 days as of February 2 [1][8]. - The medical ETF fund size reached 27 billion yuan, making it the largest in the market for medical ETFs [6][13]. Group 2: Individual Stock Movements - The Hong Kong medical ETF (159137) surged by 2%, ending a three-day decline, with Ark Health rising over 20% and BeiGene increasing by more than 4% [10]. - Ark Health raised approximately 144 million HKD through a placement of about 45.181 million shares, with 90% of the funds allocated to accelerate the development of an AI-driven chronic disease management platform [3][10]. Group 3: Industry Developments - Huawei Cloud launched the first section of its industry AI "Dream Factory" focused on smart healthcare, providing a collaborative pathology solution for grassroots hospitals [5][12]. - Institutions predict that by 2026, AI applications will transition from usable to highly effective, becoming a core theme in the AI industry, particularly in healthcare, finance, and education sectors [6][12].

脑机接口月谈——产业及公司篇 20260202 摘要 国家及地方政策积极推动脑机接口发展，七部委发布指导意见，多地医 保探索支持，目标是到 2030 年培育 2-3 家全球领军企业和一批专精特 新企业，解决支付端问题，推动商业模式从产品销售向服务转化。 高校和科研院所在脑机接口技术研发中扮演关键角色，清华大学、中科 院、浙江大学等团队在侵入式、非侵入式和介入式脑机接口研究上取得 进展，其临床试验方案对市场具有重要指导意义。 脑机接口产业链关键组件包括电极（价值量最高）、芯片和手术机器人， 微纳加工工艺复杂，技术壁垒高。Neuralink、阶梯医疗和脑虎科技等 公司在手术机器人领域有所布局。 多重因素驱动脑机接口产业发展，包括政策支持、技术研发和临床试验 推进、企业积极布局核心组件及配套设备，预计到 2030 年中国将涌现 一批全球领军企业。 脑接口技术上游环节涉及材料、算法、电极和微纳加工等，汉威科技、 科大讯飞、东威半岛等公司在柔性传感器、算法等领域有布局，值得重 点关注。 Q&A 脑机接口产业目前的发展状况如何？有哪些值得关注的政策和市场动态？ 脑机接口产业目前处于初期发展阶段，但未来空间巨大。自 202 ...

未来产业由前沿技术驱动，具有前瞻性、战略性、颠覆性等特点。"十五五"规划建议提出，推动量子科 技、生物制造、氢能和核聚变能、脑机接口、具身智能、第六代移动通信等成为新的经济增长点，这些 领域正是未来产业的典型代表。 2025年，工业和信息化领域对我国经济增长的贡献已超四成。我国拥有人工智能企业数量超过6000家， 量子科技研发多点开花，生物制造迈向万亿级产业，脑机接口技术进入植入人脑的新阶段……未来产业 蓄势发力，为高质量发展注入源源不断的新动能。 1月30日下午，中共中央政治局就前瞻布局和发展未来产业进行第二十四次集体学习，习近平总书记发 表了重要讲话。"十五五"开局之年，中央政治局首次集体学习聚焦这个课题，传递出新征程上我国将加 快培育和发展未来产业，以现代化产业新优势把握未来发展主动权的鲜明信号。 过去一年，习近平总书记多次就培育未来产业作出部署：去年4月主持中共中央政治局集体学习，聚 焦"加强人工智能发展和监管"；赴上海考察"模速空间"大模型创新生态社区；在山西考察时强调"围绕 发展新质生产力因地制宜布局新兴产业和未来产业"。 瞄准2035年基本实现社会主义现代化，"十五五"时期是夯实基础、全面发力的 ...

新华社国内部制作 新华社第一工作室出品 1月30日下午，中共中央政治局就前瞻布局和发展未来产业进行第二十四次集体学习，习近平总书记发 表了重要讲话。"十五五"开局之年，中央政治局首次集体学习聚焦这个课题，传递出新征程上我国将加 快培育和发展未来产业，以现代化产业新优势把握未来发展主动权的鲜明信号。 未来产业由前沿技术驱动，具有前瞻性、战略性、颠覆性等特点。"十五五"规划建议提出，推动量子科 技、生物制造、氢能和核聚变能、脑机接口、具身智能、第六代移动通信等成为新的经济增长点，这些 领域正是未来产业的典型代表。 过去一年，习近平总书记多次就培育未来产业作出部署：去年4月主持中共中央政治局集体学习，聚 焦"加强人工智能发展和监管"；赴上海考察"模速空间"大模型创新生态社区；在山西考察时强调"围绕 发展新质生产力因地制宜布局新兴产业和未来产业"。 瞄准2035年基本实现社会主义现代化，"十五五"时期是夯实基础、全面发力的关键时期，"建设现代化 产业体系，巩固壮大实体经济根基"是首要战略任务。未来产业将成为现代化产业体系的重要支撑，也 是重塑全球经济版图的关键要素。 此次集体学习，习近平总书记深刻阐述了发展未来产业的 ...